PATENT CLAIM ANALYSIS

Application Number: 16089637
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["514", "260100"]

Abstract:
A method of treating a pre-diabetic subject is disclosed wherein the subject is characterised by having a fasting plasma glucose level from 5.5 mmol/l to 6.9 mmol/l. The method comprises administering to the subject a therapeutically effective amount of at least one mitogen-activated protein kinase-interacting kinase (MNK) inhibitor, wherein said MNK inhibitor reduces the biological activity of MNK1 and/or MNK2. The method may prevent and/or delay progression of pre-diabetes to type 2 diabetes. The method may also prevent progression of pre-diabetes at the impaired fasting glucose (IFG) stage to the impaired glucose tolerance (IGT) stage.

Claim (Index 38):
The method of  claim 30 , wherein the MNK inhibitor is formulated as a pharmaceutical composition optionally in combination with a pharmaceutically or veterinary-acceptable filler, carrier, diluent and/or excipient.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 97.0
- Lexical Diversity: 1.68254
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12174301', '13245188', '13245113', '14778379', '13493241']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8014831474338701
- 35 USC 102 Novelty (BERT): 0.5418583549367593
- Combined Prediction Score: 0.775520668184159
- Mean Citation Score: 322.303284
- Max Citation Score: 402.81305
- Similarity Product: 235.931603103584

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test